Each of the seven AAV-based high-throughput kits is intended to detect specific serotypes to target different cell types in the body and support the researchers who develop gene therapies for various serious diseases
PerkinElmer launches new AAV-based assays. (Credit: Testalize.me on Unsplash)
US-based diagnostics and life science research company PerkinElmer has introduced ready-to-use Adeno-associated Virus Vectors (AAV) detection kits.
The high throughput detection kits are intended to help researchers who develop gene therapies for various serious diseases to characterise their viral vector particles.
They leverage bead-based luminescent amplification to enhance the detection range for viral titre measurements in a no-wash format and can be miniaturised to support 384 and 1536 well plate throughput.
Each of the seven kits is created to detect specific serotypes to target different cell types in the body for gene therapy application, said the company.
PerkinElmer life sciences senior vice president Alan Fletcher said: “One of the best ways to support gene therapy researchers is to provide solutions to help them navigate the unique workflows they work with to shorten and simplify the path from lab to the clinic.
“Our new AAV detection kits are designed to do that by eliminating long, tedious protocols while expanding the detection range to enable potential cures for people living with cancer, Alzheimer’s, muscular dystrophy, infectious diseases and more.”
PerkinElmer has leveraged its unique AlphaLISA technology for the development of validated and fully automatable assays.
The technology does not require any separation and is the only optimised, no-wash AAV detection assays currently available on the market, said the company.
PerkinElmer said the new offering will provide researchers with expanded options to measure viral titres beyond ELISA and other wash-based systems, which can be time-consuming and limited.
The AAV assays are designed to streamline gene therapy research and development workflows with an easier-to-use and more high throughput method, said the firm.
They expand the company’s cell and gene therapy portfolio, which also includes gene editing and modulation, cell counting, antibody and flow cytometry offerings.
In August this year, PerkinElmer signed an agreement to sell its Applied, Food and Enterprise Services businesses to New Mountain Capital for $2.45bn in cash.